Allspring Global Investments Holdings LLC Purchases 15,369 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Allspring Global Investments Holdings LLC increased its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 4,989.9% in the 2nd quarter, HoldingsChannel reports. The firm owned 15,677 shares of the company’s stock after acquiring an additional 15,369 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Organogenesis were worth $44,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Organogenesis by 11.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 50,951 shares of the company’s stock worth $145,000 after acquiring an additional 5,359 shares during the last quarter. Victory Capital Management Inc. bought a new position in shares of Organogenesis in the fourth quarter worth about $43,000. Pallas Capital Advisors LLC bought a new position in shares of Organogenesis in the second quarter worth about $38,000. CWM LLC lifted its holdings in shares of Organogenesis by 301.8% in the second quarter. CWM LLC now owns 25,617 shares of the company’s stock worth $72,000 after acquiring an additional 19,242 shares during the last quarter. Finally, Connors Investor Services Inc. lifted its holdings in shares of Organogenesis by 58.1% in the first quarter. Connors Investor Services Inc. now owns 68,000 shares of the company’s stock worth $193,000 after acquiring an additional 25,000 shares during the last quarter. Institutional investors own 49.57% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Lake Street Capital began coverage on shares of Organogenesis in a report on Friday, June 28th. They issued a “buy” rating and a $5.00 target price for the company.

Organogenesis Stock Performance

Organogenesis stock opened at $2.54 on Tuesday. The business has a 50 day moving average of $2.81 and a 200-day moving average of $2.78. Organogenesis Holdings Inc. has a 1 year low of $1.96 and a 1 year high of $4.70. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.73 and a quick ratio of 2.42. The company has a market capitalization of $336.73 million, a P/E ratio of 63.52 and a beta of 1.62.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The firm had revenue of $130.23 million during the quarter, compared to analyst estimates of $122.48 million. Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. On average, equities research analysts predict that Organogenesis Holdings Inc. will post -0.19 earnings per share for the current year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.